Serum IL10 and circulating CD4+CD25high regulatory T cell numbers as predictors of clinical outcome and survival in patients with head and neck squamous cell carcinoma

Head and Neck

Volumn 33, Issue 3, 2011, Pages 415-423

  Alhamarneh, Osama ^a   Agada, Frank ^a   Madden, Leigh ^a   Stafford, Nicholas ^a   Greenman, John ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

Author keywords

antitumor immunity; HNSCC; IL10; IL12; regulatory T cells

Indexed keywords

CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 12;

ADULT; AGED; ARTICLE; CANCER CONTROL; CANCER DIAGNOSIS; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CD4+ CD25+ T LYMPHOCYTE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HEAD AND NECK CARCINOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN TISSUE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MOUTH CAVITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REGULATORY T LYMPHOCYTE; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CD4-POSITIVE T-LYMPHOCYTES; CHI-SQUARE DISTRIBUTION; COHORT STUDIES; DISEASE-FREE SURVIVAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HEAD AND NECK NEOPLASMS; HUMANS; INTERLEUKIN-10; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK ASSESSMENT; SURVIVAL ANALYSIS; T-LYMPHOCYTES, REGULATORY; TUMOR MARKERS, BIOLOGICAL;

EID: 79951713150     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21464     Document Type: Article

References (43)

1. Baatar D, Olkhanud P, Sumitomo K, Taub D, Gress R, Biragyn A,. Human peripheral blood T regulatory cells (Tregs), functionally primed CCR4+ Tregs and unprimed CCR4-Tregs, regulate effector T cells using FasL. J Immunol 2007; 178: 4891-4900. (Pubitemid 46595271)
2. Argiris A, Karamouzis MV, Raben D, Ferris RL,. Head and neck cancer. Lancet 2008; 371: 1695-1709. (Pubitemid 351671886)
3. Whiteside TL,. The tumor microenvironment and its role in promoting tumor growth. Oncogene 2008; 27: 5904-5912.
4. Kuss I, Hathaway B, Ferris RL, Gooding W, Whiteside TL,. Decreased absolute counts of T lymphocyte subsets and their relation to disease in squamous cell carcinoma of the head and neck. Clin Cancer Res 2004; 10: 3755-3762. (Pubitemid 38697609)
5. Albers AE, Ferris RL, Kim GG, Chikamatsu K, DeLeo AB, Whiteside TL,. Immune responses to p53 in patients with cancer: enrichment in tetramer+ p53 peptide-specific T cells and regulatory T cells at tumor sites. Cancer Immunol Immunother 2005; 54: 1072-1081. (Pubitemid 41396812)
6. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL,. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986; 136: 2348-2357. (Pubitemid 16136806)
7. Fiorentino DF, Zlotnik A, Vieira P, et al. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol 1991; 146: 3444-3451.
8. Goto S, Sato M, Kaneko R, Itoh M, Sato S, Takeuchi S,. Analysis of Th1 and Th2 cytokine production by peripheral blood mononuclear cells as a parameter of immunological dysfunction in advanced cancer patients. Cancer Immunol Immunother 1999; 48: 435-442. (Pubitemid 29503443)
9. Bertenshaw GP, Yip P, Seshaiah P, et al. Multianalyte profiling of serum antigens and autoimmune and infectious disease molecules to identify biomarkers dysregulated in epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 2008; 17: 2872-2881.
10. Sheu BC, Lin RH, Lien HC, Ho HN, Hsu SM, Huang SC,. Predominant Th2/Tc2 polarity of tumor-infiltrating lymphocytes in human cervical cancer. J Immunol 2001; 167: 2972-2978.
11. Linkov F, Lisovich A, Yurkovetsky Z, et al. Early detection of head and neck cancer: development of a novel screening tool using multiplexed immunobead-based biomarker profiling. Cancer Epidemiol Biomarkers Prev 2007; 16: 102-107. (Pubitemid 46174271)
12. Sparano A, Lathers DM, Achille N, Petruzzelli GJ, Young MR,. Modulation of Th1 and Th2 cytokine profiles and their association with advanced head and neck squamous cell carcinoma. Otolaryngol Head Neck Surg 2004; 131: 573-576. (Pubitemid 39446277)
13. Hoffmann TK, Sonkoly E, Homey B, et al. Aberrant cytokine expression in serum of patients with adenoid cystic carcinoma and squamous cell carcinoma of the head and neck. Head Neck 2007; 29: 472-478. (Pubitemid 46732587)
14. Alhamarneh O, Amarnath SM, Stafford ND, Greenman J,. Regulatory T cells: what role do they play in antitumor immunity in patients with head and neck cancer? Head Neck 2008; 30: 251-261. (Pubitemid 351251710)
15. Shevach EM,. Regulatory T cells in autoimmmunity. Annu Rev Immunol 2000; 18: 423-449. (Pubitemid 30365387)
16. Klein L, Khazaie K, von Boehmer H,. In vivo dynamics of antigen-specific regulatory T cells not predicted from behavior in vitro. Proc Natl Acad Sci U S A 2003; 100: 8886-8891. (Pubitemid 36899193)
17. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10: 942-949. (Pubitemid 39273735)
18. Ladoire S, Arnould L, Apetoh L, et al. Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating foxp3+ regulatory T cells. Clin Cancer Res 2008; 14: 2413-2420. (Pubitemid 351551075)
19. Bergmann C, Strauss L, Wang Y, et al. T regulatory type 1 cells in squamous cell carcinoma of the head and neck: mechanisms of suppression and expansion in advanced disease. Clin Cancer Res 2008; 14: 3706-3715.
20. Strauss L, Bergmann C, Gooding W, Johnson JT, Whiteside TL,. The frequency and suppressor function of CD4+CD25highFoxp3+ T cells in the circulation of patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 2007; 13: 6301-6311. (Pubitemid 350075018)
21. Kono K, Kawaida H, Takahashi A, et al. CD4(+)CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers. Cancer Immunol Immunother 2006; 55: 1064-1071. (Pubitemid 43800721)
22. Brossart P, Zobywalski A, Grünebach F, et al. Tumor necrosis factor alpha and CD40 ligand antagonize the inhibitory effects of interleukin 10 on T cell stimulatory capacity of dendritic cells. Cancer Res 2000; 60: 4485-4492. (Pubitemid 32103629)
23. Kryczek I, Wei S, Zou L, et al. Cutting edge: induction of B7-H4 on APCs through IL-10: novel suppressive mode for regulatory T cells. J Immunol 2006; 177: 40-44. (Pubitemid 43939113)
24. Hatanaka H, Abe Y, Naruke M, et al. Significant correlation between interleukin 10 expression and vascularization through angiopoietin/TIE2 networks in non-small cell lung cancer. Clin Cancer Res 2001; 7: 1287-1292. (Pubitemid 32708682)
25. D'Andrea A, Aste-Amezaga M, Valiante NM, Ma X, Kubin M, Trinchieri G,. Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J Exp Med 1993; 178: 1041-1048. (Pubitemid 23260442)
26. O'Hara RJ, Greenman J, MacDonald AW, et al. Advanced colorectal cancer is associated with impaired interleukin 12 and enhanced interleukin 10 production. Clin Cancer Res 1998; 4: 1943-1948. (Pubitemid 28369179)
27. Smyth GP, Stapleton PP, Barden CB, et al. Renal cell carcinoma induces prostaglandin E2 and T helper type 2 cytokine production in peripheral blood mononuclear cells. Ann Surg Oncol 2003; 10: 455-462. (Pubitemid 40486945)
28. Jebreel A, Mistry D, Loke D, et al. Investigation of interleukin 10, 12 and 18 levels in patients with head and neck cancer. J Laryngol Otol 2007; 121: 246-252. (Pubitemid 46833125)
29. Lathers DM, Achille NJ, Young MR,. Incomplete Th2 skewing of cytokines in plasma of patients with squamous cell carcinoma of the head and neck. Hum Immunol 2003; 64: 1160-1166. (Pubitemid 37475277)
30. Bose A, Chakraborty T, Chakraborty K, Pal S, Baral R,. Dysregulation in immune functions is reflected in tumor cell cytotoxicity by peripheral blood mononuclear cells from head and neck squamous cell carcinoma patients. Cancer Immun 2008; 8: 10.
31. Riedel F, Adam S, Feick P, et al. Expression of IL-18 in patients with head and neck squamous cell carcinoma. Int J Mol Med 2004; 13: 267-272.
32. Lathers DM, Young MR,. Increased aberrance of cytokine expression in plasma of patients with more advanced squamous cell carcinoma of the head and neck. Cytokine 2004; 25: 220-228. (Pubitemid 38229413)
33. Chandler SW, Rassekh CH, Rodman SM, Ducatman BS,. Immunohistochemical localization of interleukin-10 in human oral and pharyngeal carcinomas. Laryngoscope 2002; 112: 808-815. (Pubitemid 34477609)
34. Cousins DJ, Lee TH, Staynov DZ,. Cytokine coexpression during human Th1/Th2 cell differentiation: direct evidence for coordinated expression of Th2 cytokines. J Immunol 2002; 169: 2498-2506. (Pubitemid 34920994)
35. Sica A, Saccani A, Bottazzi B, et al. Autocrine production of IL-10 mediates defective IL-12 production and NF-kappa B activation in tumor-associated macrophages. J Immunol 2000; 164: 762-767. (Pubitemid 30043699)
36. DiLillo DJ, Matsushita T, Tedder TF,. B10 cells and regulatory B cells balance immune responses during inflammation, autoimmunity, and cancer. Ann N Y Acad Sci 2010; 1183: 38-57.
37. Berzofsky JA, Terabe M,. The contrasting roles of NKT cells in tumor immunity. Curr Mol Med 2009; 9: 667-672.
38. Manchanda P, Sharma SC, Das SN,. Differential regulation of IL-2 and IL-4 in patients with tobacco-related oral squamous cell carcinoma. Oral Dis 2006; 12: 455-462. (Pubitemid 44252537)
39. Agarwal A, Rani M, Saha GK, et al. Disregulated expression of the Th2 cytokine gene in patients with intraoral squamous cell carcinoma. Immunol Invest 2003; 32: 17-30. (Pubitemid 36527847)
40. Carrier Y, Yuan J, Kuchroo VK, Weiner HL,. Th3 cells in peripheral tolerance. I. Induction of Foxp3-positive regulatory T cells by Th3 cells derived from TGF-beta T cell-transgenic mice. J Immunol 2007; 178: 179-185. (Pubitemid 46033599)
41. Venet F, Pachot A, Debard AL, et al. Human CD4+CD25+ regulatory T lymphocytes inhibit lipopolysaccharide-induced monocyte survival through a Fas/Fas ligand-dependent mechanism. J Immunol 2006; 177: 6540-6547. (Pubitemid 44628873)
42. Warnecke G, Avsar M, Morancho M, et al. Preoperative low-dose irradiation promotes long-term allograft acceptance and induces regulatory T cells in a porcine model of pulmonary transplantation. Transplantation 2006; 82: 93-101. (Pubitemid 44296983)
43. Schaefer C, Kim GG, Albers A, Hoermann K, Myers EN, Whiteside TL,. Characteristics of CD4+CD25+ regulatory T cells in the peripheral circulation of patients with head and neck cancer. Br J Cancer 2005; 92: 913-920. (Pubitemid 40462639)